Porton Pharma Solutions Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Nianfeng Ju

Chief Executive Officer (CEO)

CN¥1.9m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	10.8%
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	2.6yrs

Actualizaciones recientes de la dirección

Recent updates

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Nov 14

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Sep 30

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04

CEO

Nianfeng Ju (52 yo)

no data

Permanencia

CN¥1,931,300

Compensación

Mr. Nianfeng Ju serves as General Manager of Porton Imp & Exp Ltd. Nianfeng Ju served as the General Manager of Porton Co., Ltd. He serves as a General Manager of Porton Pharma Solutions Ltd.Mr. Ju serves...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Nianfeng Ju	Chairman & GM	no data	CN¥1.93m	10.8% CN¥ 1.0b
Hui Chen	Deputy GM & CFO	2.6yrs	CN¥1.59m	sin datos
Yinchun Bai	Senior Deputy GM & COO	2.6yrs	CN¥1.65m	0.029% CN¥ 2.7m
Pi Wei	Deputy General Manager & Secretary	2.6yrs	CN¥714.90k	0.0083% CN¥ 774.0k
Zhongneng Wang	Deputy General Manager	2.6yrs	CN¥1.39m	0.026% CN¥ 2.4m
Fengping Wang	Deputy General Manager	2.6yrs	CN¥2.09m	0.020% CN¥ 1.9m
Qi Chen	Deputy General Manager	1.3yrs	sin datos	sin datos
Xiongbin Ma	Deputy General Manager	1.3yrs	sin datos	sin datos
Yuanming Huang	Deputy General Manager	1.3yrs	sin datos	sin datos

2.6yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300363 se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Nianfeng Ju	Chairman & GM	no data	CN¥1.93m	10.8% CN¥ 1.0b
Weiqiang Yang	Non Independent Director	3.3yrs	CN¥180.00k	sin datos
Guohua Cao	Independent Director	4.2yrs	CN¥180.00k	sin datos
Hui Zeng	Employee Representative Supervisor	no data	CN¥212.80k	sin datos
Lin Yuan	Independent Director	2.6yrs	CN¥180.00k	sin datos
Jinwei Pang	Independent Director	2.6yrs	CN¥180.00k	sin datos
Yongqing Tan	Non-Employee Supervisory Board Chairman	no data	sin datos	sin datos
Ying Xue	Non-Independent Director	4.2yrs	CN¥180.00k	0.0027% CN¥ 252.4k
Jun Zhu	Director	1.8yrs	sin datos	sin datos
Lina Hu	Non-Independent Director	2.6yrs	CN¥180.00k	sin datos
Guojun Cao	Non-Independent Director	2.6yrs	CN¥180.00k	sin datos
Yuchen Wu	Non-Employee Supervisor	2.6yrs	sin datos	sin datos

2.6yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 300363 no se considera experimentada (2.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Porton Pharma Solutions Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new directors

High number of new and inexperienced directors

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Recent updates

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Price target increased by 34% to CN¥20.00

Third quarter 2024 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 3Q 2023)

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

New minor risk - Share price stability

Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023)

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Price target decreased by 29% to CN¥20.30

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Investor sentiment deteriorates as stock falls 15%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Price target decreased by 11% to CN¥33.00

Consensus EPS estimates increase by 12%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 10%

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Price target decreased by 9.8% to CN¥37.00

Consensus EPS estimates fall by 43%, revenue upgraded

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Consensus EPS estimates fall by 26%

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.7% to CN¥70.63

Investor sentiment improved over the past week

High number of new directors

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 21%

Price target decreased to CN¥104

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Consensus revenue estimates increase by 52%

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

Revenue beats expectations

New 90-day high: CN¥46.67